More than two-thirds of respondents to a recent GEN poll see the falling Euro having at least some effect on the U.S. biopharma industry. While results are somewhat split, 40.3% of respondents expect the Euro crisis to have “somewhat” of an effect, followed closely by the 34.3% who anticipate “a lot” of impact. Another 20.9% foresee “not much” of an effect, and the remaining 4.5% of respondents were undecided.
Until now, the result of the Euro’s woes on biopharma can be seen most in the currency’s home continent, where several biopharma giants have attributed sales slumps to the Euro or trends stemming from the Euro’s slide, while Germany has tightened its rules governing pricing of new drugs.